Monitoring Targeted Lung Cancer Treatments With FDG-PET/CT
- Determine the prognostic significance of changes in glucose metabolism measured by
fludeoxyglucose F 18 positron emission tomography (FDG-PET)/CT scan in patients with
non-small cell lung cancer treated with targeted drugs comprising gefitinib, erlotinib
hydrochloride, or other ErbB inhibitors, cyclooxygenase-2 inhibitors, or estrogen
receptor blockers in combination with conventional chemotherapy.
OUTLINE: This is a prospective study.
Patients undergo fludeoxyglucose F 18 positron emission tomography (FDG-PET) scan and CT
scan at baseline and at 2 weeks and 12 weeks after receiving targeted anticancer treatment.
Metabolic changes detected by FDG-PET and size changes identified by CT scan are related to
patient outcome and tumor response to treatment.
PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.
Observational Model: Case-Only, Time Perspective: Prospective
Correlation of glucose metabolic response with progression-free survival, overall survival, and changes in tumor size as measured by fludeoxyglucose F 18 positron emission tomography/CT scan
Johannes Czernin, MD
Jonsson Comprehensive Cancer Center
United States: Institutional Review Board
|Jonsson Comprehensive Cancer Center at UCLA||Los Angeles, California 90095-1781|